BlueCrest Capital Management’s Barinthus Biotherapeutics BRNS Stock Holding History

BlueCrest Capital Management’s Portfolio BRNS Stock Details BRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-542,673	Closed	-$646K	–	100
2024 Q3	$646K	Hold	542,673	–	–	0.15%	64
2024 Q2	$760K	Hold	542,673	–	–	0.13%	81
2024 Q1	$1.29M	Hold	542,673	–	–	0.31%	146
2023 Q4	$2M	Hold	542,673	–	–	0.33%	147
2023 Q3	$1.68M	Hold	542,673	–	–	0.26%	151
2023 Q2	$1.12M	Hold	542,673	–	–	0.15%	142
2023 Q1	$1.22M	Hold	542,673	–	–	0.13%	142
2022 Q4	$1.28M	Hold	542,673	–	–	0.15%	107
2022 Q3	$1.74M	Hold	542,673	–	–	0.17%	119
2022 Q2	$2.42M	Hold	542,673	–	–	0.33%	105
2022 Q1	$2.82M	Sell	542,673 -400	-0.1%	-$3.23K	0.23%	125
2021 Q4	$6.03M	Buy	+543,073	New	+$6.85M	0.35%	86

Other funds holding BRNS

M&G plc London, United Kingdom $19.3B AUM 16.7% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return

DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return

Baird Financial Group

Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ipswich Investment Management Beverly, Massachusetts $426M AUM 24.58% 1-Year Est. Return

Janney Montgomery Scott

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return